PE20211778A1 - Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos - Google Patents
Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismosInfo
- Publication number
- PE20211778A1 PE20211778A1 PE2021000774A PE2021000774A PE20211778A1 PE 20211778 A1 PE20211778 A1 PE 20211778A1 PE 2021000774 A PE2021000774 A PE 2021000774A PE 2021000774 A PE2021000774 A PE 2021000774A PE 20211778 A1 PE20211778 A1 PE 20211778A1
- Authority
- PE
- Peru
- Prior art keywords
- specific antibodies
- protein
- bispecific
- antibody
- ligand
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona un anticuerpo biespecifico anti-PD-L1/anti-4-1BB capaz de bloquear de manera eficaz las interacciones entre PD-L1 y su PD-1 receptor y entre 4-1BB y su ligando. El anticuerpo biespecifico puede tener alta afinidad de union tanto a una proteina PD-L1 como una proteina 4-1BB.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773239P | 2018-11-30 | 2018-11-30 | |
PCT/CN2019/075180 WO2020107715A1 (en) | 2018-11-30 | 2019-02-15 | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211778A1 true PE20211778A1 (es) | 2021-09-08 |
Family
ID=70852440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000774A PE20211778A1 (es) | 2018-11-30 | 2019-02-15 | Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos |
Country Status (18)
Country | Link |
---|---|
US (2) | US20220056136A1 (es) |
EP (2) | EP3891187A4 (es) |
JP (2) | JP7328658B2 (es) |
KR (2) | KR20210099052A (es) |
CN (2) | CN113286825A (es) |
AU (2) | AU2019390274A1 (es) |
BR (2) | BR112021010402A2 (es) |
CA (2) | CA3121562A1 (es) |
CL (1) | CL2021001368A1 (es) |
CO (1) | CO2021006911A2 (es) |
EA (1) | EA202191457A1 (es) |
IL (1) | IL283530A (es) |
MX (1) | MX2021006379A (es) |
PE (1) | PE20211778A1 (es) |
PH (1) | PH12021551171A1 (es) |
SG (1) | SG11202105152YA (es) |
WO (2) | WO2020107715A1 (es) |
ZA (1) | ZA202102870B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017215590A1 (en) * | 2016-06-13 | 2017-12-21 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
SG11202006008WA (en) * | 2018-03-29 | 2020-07-29 | I Mab Biopharma Us Ltd | Anti-pd-l1 antibodies and uses thereof |
EP4004053A4 (en) * | 2019-07-26 | 2023-10-18 | ABL Bio, Inc. | BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODIES AND USE THEREOF |
CN114206941A (zh) * | 2019-07-26 | 2022-03-18 | Abl生物公司 | 抗her2/抗4-1bb双特异性抗体及其用途 |
EP3853257A4 (en) * | 2019-08-12 | 2022-06-29 | I-Mab Biopharma US Limited | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof |
US11466086B2 (en) | 2019-10-11 | 2022-10-11 | Nanjing Leads Biolabs Co., Ltd. | Antibodies binding 4-1BB and uses thereof |
KR20230015957A (ko) * | 2020-06-30 | 2023-01-31 | 하버 바이오메드 유에스, 아이엔씨. | 이중특이적 항체 및 이의 용도 |
IL310780A (en) * | 2020-08-18 | 2024-04-01 | Abl Bio Inc | ANTI-B7-H4/ANTI-4-1BB bispecific antibodies and their use |
CN114195900B (zh) * | 2020-09-17 | 2024-02-23 | 普米斯生物技术(珠海)有限公司 | 一种抗4-1bb/pd-l1双特异性抗体及其用途 |
CN117083080A (zh) * | 2020-12-07 | 2023-11-17 | 健玛保 | 抗体和紫杉烷联合疗法 |
KR102576861B1 (ko) * | 2021-01-11 | 2023-09-11 | 주식회사 유틸렉스 | 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도 |
CN116745309A (zh) * | 2021-01-25 | 2023-09-12 | 柳韩洋行 | 用于纯化抗-4-1bb/抗-her2双特异性抗体的方法 |
WO2023000675A1 (zh) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程(集团)股份有限公司 | 靶向pd-l1和4-1bb的双特异性抗体 |
CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
WO2023200865A2 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | Cancer therapy |
WO2024008032A1 (en) * | 2022-07-06 | 2024-01-11 | Beijing Hanmi Pharmaceutical Co., Ltd. | Formulations for anti-pd-l1/anti-4-1bb bispecific antibodies |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1539237A4 (en) * | 2002-07-30 | 2006-05-24 | Bristol Myers Squibb Co | HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB |
US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
EP2699598B1 (en) * | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
MA40035A (fr) * | 2014-10-14 | 2016-04-21 | Dana Farber Cancer Inst Inc | Molécules d'anticorps de pd-l1 et leurs utilisations |
CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
MX2017010793A (es) * | 2015-02-22 | 2018-07-06 | Sorrento Therapeutics Inc | Terapeuticos de anticuerpo que ligan cd137. |
ES2802994T3 (es) * | 2015-09-22 | 2021-01-22 | Dingfu Biotarget Co Ltd | Anticuerpo completamente humano contra CD137 humano y uso del mismo |
SG11201805532XA (en) * | 2016-01-11 | 2018-07-30 | Inhibrx Inc | Multivalent and multispecific 41bb-binding fusion proteins |
US11104739B2 (en) * | 2016-04-14 | 2021-08-31 | Bristol-Myers Squibb Company | Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody |
RU2018139339A (ru) * | 2016-04-22 | 2020-05-22 | Эллигейтор Биосайенс Аб | Новые биспецифические полипептиды против cd137 |
US10875921B2 (en) * | 2016-05-27 | 2020-12-29 | Abbvie Biotherapeutics Inc. | Anti-4-1BB antibodies and their uses |
CN107488229B (zh) * | 2016-06-13 | 2020-11-17 | 天境生物科技(上海)有限公司 | Pd-l1抗体及其用途 |
WO2017215590A1 (en) | 2016-06-13 | 2017-12-21 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
BR112018076260A2 (pt) * | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
CN110392696B (zh) * | 2017-01-06 | 2020-09-11 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
CN107326014B (zh) * | 2017-07-31 | 2019-09-24 | 时力生物科技(北京)有限公司 | 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用 |
-
2019
- 2019-02-15 KR KR1020217020162A patent/KR20210099052A/ko unknown
- 2019-02-15 EP EP19890398.1A patent/EP3891187A4/en active Pending
- 2019-02-15 SG SG11202105152YA patent/SG11202105152YA/en unknown
- 2019-02-15 CA CA3121562A patent/CA3121562A1/en active Pending
- 2019-02-15 CN CN201980079076.9A patent/CN113286825A/zh active Pending
- 2019-02-15 BR BR112021010402-0A patent/BR112021010402A2/pt unknown
- 2019-02-15 US US17/298,741 patent/US20220056136A1/en active Pending
- 2019-02-15 AU AU2019390274A patent/AU2019390274A1/en active Pending
- 2019-02-15 JP JP2021531379A patent/JP7328658B2/ja active Active
- 2019-02-15 WO PCT/CN2019/075180 patent/WO2020107715A1/en active Application Filing
- 2019-02-15 MX MX2021006379A patent/MX2021006379A/es unknown
- 2019-02-15 PE PE2021000774A patent/PE20211778A1/es unknown
- 2019-02-15 EA EA202191457A patent/EA202191457A1/ru unknown
- 2019-12-02 CN CN201980078436.3A patent/CN113166250B/zh active Active
- 2019-12-02 EP EP19890588.7A patent/EP3887403A4/en active Pending
- 2019-12-02 US US17/296,752 patent/US20220242961A1/en active Pending
- 2019-12-02 WO PCT/KR2019/016863 patent/WO2020111913A1/en unknown
- 2019-12-02 AU AU2019386549A patent/AU2019386549A1/en active Pending
- 2019-12-02 CA CA3121218A patent/CA3121218A1/en active Pending
- 2019-12-02 KR KR1020217018760A patent/KR20210087094A/ko active Search and Examination
- 2019-12-02 BR BR112021010394-5A patent/BR112021010394A2/pt unknown
- 2019-12-02 JP JP2021530789A patent/JP7378474B2/ja active Active
-
2021
- 2021-04-29 ZA ZA2021/02870A patent/ZA202102870B/en unknown
- 2021-05-21 PH PH12021551171A patent/PH12021551171A1/en unknown
- 2021-05-25 CO CONC2021/0006911A patent/CO2021006911A2/es unknown
- 2021-05-26 CL CL2021001368A patent/CL2021001368A1/es unknown
- 2021-05-28 IL IL283530A patent/IL283530A/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA202102870B (en) | 2023-05-31 |
KR20210087094A (ko) | 2021-07-09 |
US20220056136A1 (en) | 2022-02-24 |
EP3887403A4 (en) | 2022-08-31 |
EP3891187A1 (en) | 2021-10-13 |
CA3121218A1 (en) | 2020-06-04 |
EA202191457A1 (ru) | 2021-09-06 |
EP3887403A1 (en) | 2021-10-06 |
CN113166250A (zh) | 2021-07-23 |
PH12021551171A1 (en) | 2021-11-29 |
JP2022510253A (ja) | 2022-01-26 |
US20220242961A1 (en) | 2022-08-04 |
JP2022513694A (ja) | 2022-02-09 |
AU2019386549A1 (en) | 2021-06-24 |
JP7378474B2 (ja) | 2023-11-13 |
EP3891187A4 (en) | 2022-10-05 |
CO2021006911A2 (es) | 2021-08-09 |
SG11202105152YA (en) | 2021-06-29 |
JP7328658B2 (ja) | 2023-08-17 |
MX2021006379A (es) | 2021-10-13 |
CA3121562A1 (en) | 2020-06-04 |
IL283530A (en) | 2021-07-29 |
CL2021001368A1 (es) | 2022-03-04 |
BR112021010402A2 (pt) | 2021-08-24 |
BR112021010394A2 (pt) | 2021-08-24 |
WO2020111913A1 (en) | 2020-06-04 |
KR20210099052A (ko) | 2021-08-11 |
AU2019390274A1 (en) | 2021-07-22 |
CN113166250B (zh) | 2023-10-03 |
CN113286825A (zh) | 2021-08-20 |
WO2020107715A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211778A1 (es) | Anticuerpos biespecificos anti-pd-l1/anti-4-1bb y usos de los mismos | |
MX2020004129A (es) | Anticuerpos anti-cd38 y metodos de uso. | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
CL2020003127A1 (es) | Anticuerpos bispecificos anti-pvrig/anti-tigit y métodos de uso | |
PE20181349A1 (es) | Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
AR111418A1 (es) | Dominios de unión a antígeno humanizados y métodos de uso | |
ECSP19087580A (es) | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos | |
PE20191759A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
CL2016002460A1 (es) | Anticuerpos biespecíficos que se unen a cd38 y cd3 | |
PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
EA201691321A1 (ru) | Антитела и способы их применения | |
BR112014028826A8 (pt) | anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1 | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
BR112015007672A2 (pt) | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso | |
GT201400045A (es) | Anticuerpo anti-abtcr | |
CO2020012360A2 (es) | Anticuerpos multiespecíficos y utilización de los mismos | |
SG11201909156RA (en) | Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof | |
CL2019001352A1 (es) | Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo. | |
CL2020002540A1 (es) | Anticuerpos anti-hla-g y utilización de los mismos | |
EA201990672A1 (ru) | Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты | |
ECSP21069105A (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
MX2021016066A (es) | Anticuerpos heterodimericos que se unen a cd38 y cd3. | |
AR101023A1 (es) | Proteínas de unión a cd33 y cd3 biespecíficas |